News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boca Pharmacal, Inc. Receives FDA Approval for Carbinoxamine Oral Solution


2/28/2008 6:49:14 AM

CORAL SPRINGS, Fla., Feb. 27 /PRNewswire/ -- Boca Pharmacal, Inc. announced today that the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Pamlab's Palgic(R) Oral Solution (Carbinoxamine Maleate Oral Solution) 4 mg/5mL. The Company plans to launch its product immediately.

Carbinoxamine Maleate Oral Solution 4mg/5mL is indicated to treat seasonal and perennial allergic rhinitis.

"This approval is another example of our commitment to providing affordable drug products to customers and consistent innovation in the pharmaceutical industry," commented Robert J. Edwards Jr., CEO. "At Boca Pharmacal we pride ourselves on our ability to offer lower volume items that may have been overlooked by some of the larger generic companies. Carbinoxamine Maleate Oral Solution is the first of many approvals we expect in 2008. Having filed multiple ANDA applications coupled with our multinational partnerships we expect 2008 to be a very big year."

Founded in 1998 Coral Springs, FL based Boca Pharmacal manufactures, develops and distributes a wide variety of generic drugs.

CONTACT: Robert Edwards of Boca Pharmacal, Inc., +1-954-346-8810

Web site: http://www.bocapharmacal.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES